You're listening to Movers and Shakers, a podcast about living with Parkinson's.

The show is generously sponsored by Albion Chambers Bristol, a preeminent set of barristers,

specialising in providing the highest quality legal advice and representation

in criminal, family, inquest and regulatory law.

Hello and welcome to another edition of Movers and Shakers, that award-winning podcast about

living with Parkinson's. We're in the pub again, and in today's episode, we hope that eventually

that idea will seem as dated as devoting a podcast to the rigors of rickets or the curses of consumption. I'm Mark Modell, and we're back in the pub to discuss some potentially huge new developments in research for disease and modifying drugs, otherwise known as, yes, a cure. But it's not just the research that's changing, but the way it's funded, and that's just as

exciting and just as important. We'll be asking how's the research paid for, what's the role of the charities, and what should be done by the government. But first of all, who's here? I'm Julian Lacey Salomon. I'm Rory Kethynne Jans. Michael Mollstone. I'm Paul Mayhew Archer. I'm delighted to have us with us. Helen Matthews, the CEO of Kure Parkinson's. Good afternoon.

Hello. It's lovely to be here. It's great to have you. And from Parkinson's UK Deputy Head of Research, Claire Bale. Welcome. Hi, thank you for having me. Now, before we go any further, because this is a posh pub and doesn't like fights and so. Are you friends or are you rivals? Oh, I've had the absolute privilege of working with Claire for years and years and years and years and worked really, really closely with her. It's one of the things that people don't realize is behind the scenes, the charities are speaking every day. There are touch points, you know, because there are all sorts of issues that we're addressing on a daily basis. So different members of the team will be

in touch with each other. So Claire and I really work very, very closely, particularly on research

matters. You know, learning from each other and sharing information has been hugely important

as part of that relationship. Put on the charities competing for money. No, I don't think we are

because we're actually trying to achieve the same thing together as much as we can.

We're not competing in terms of the goal. We are trying to achieve the same thing and much of

that is done together. And we have really complementary approaches to how we fund research and facilitate

research. And the more we talk to each other, the better we're able to join those things up.

In terms of Qa Parkinson's, does what it says on the tin, presumably.

That's very definitely our aim. It's trying to slow down Parkinson's, stop it or reverse it.

We have a pretty clear strategy that we know that we're going to need to be layering in things

so that we can address every single type of Parkinson's that we see in front of us.

So we might need to have something that is

going to actually stop the disease, actually stop the progression. We also then might need to add in a

...